相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes The STEP 8 Randomized Clinical Trial
Domenica M. Rubino et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
Challenges in applying the GRADE approach in public health guidelines and systematic reviews: a concept article from the GRADE Public Health Group
Michele Hilton Boon et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2021)
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial
Thomas A. Wadden et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, doubleblind, double-dummy, placebo-controlled, phase 3 trial
Melanie Davies et al.
LANCET (2021)
Once-Weekly Semaglutide in Adults with Overweight or Obesity
John P. H. Wilding et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Weight Loss Outcomes Among Early High Responders to Exenatide Treatment: A Randomized, Placebo Controlled Study in Overweight and Obese Women
Megan Rodgers et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial
Domenica Rubino et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Guidelines that use the GRADE approach often fail to provide complete economic information for recommendations: A systematic survey
John J. Riva et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2021)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)
M. S. Capehorn et al.
DIABETES & METABOLISM (2020)
Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial
W. Timothy Garvey et al.
DIABETES CARE (2020)
Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial
Thomas A. Wadden et al.
OBESITY (2020)
A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
Aaron S. Kelly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Metabolic Factors Determining the Susceptibility to Weight Gain: Current Evidence
Tim Hollstein et al.
CURRENT OBESITY REPORTS (2020)
Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial
Bernard Zinman et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Intensive Behavioral Therapy for Obesity Combined with Liraglutide 3.0 mg: A Randomized Controlled Trial
Thomas A. Wadden et al.
OBESITY (2019)
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study
Serge A. Jabbour et al.
DIABETES OBESITY & METABOLISM (2018)
Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study
Cristian Guja et al.
DIABETES OBESITY & METABOLISM (2018)
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
Andrew J. Ahmann et al.
DIABETES CARE (2018)
Method-of-Use Study of Naltrexone Sustained Release (SR)/Bupropion SR on Body Weight in Individuals with Obesity
Amy Halseth et al.
OBESITY (2017)
Mechanisms, Pathophysiology, and Management of Obesity
Steven B. Heymsfield et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Coadministration of lorcaserin and phentermine for weight management: A 12-week, randomized, pilot safety study
Steven R. Smith et al.
OBESITY (2017)
The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity
James Crane et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2016)
Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks
Nitesh D. Kuhadiya et al.
DIABETES CARE (2016)
EFFECTS OF LIRAGLUTIDE 3.0 MG ON WEIGHT AND RISK FACTORS IN HISPANIC VERSUS NON-HISPANIC POPULATIONS: SUBGROUP ANALYSIS FROM SCALE RANDOMIZED TRIALS
Patrick M. O'Neil et al.
ENDOCRINE PRACTICE (2016)
Impact of lorcaserin on glycemic control in overweight and obese patients with type 2 diabetes: analysis of week 52 responders and nonresponders
Xavier Pi-Sunyer et al.
POSTGRADUATE MEDICINE (2016)
Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes The SCALE Diabetes Randomized Clinical Trial
Melanie J. Davies et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Xavier Pi-Sunyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
2014 EASO Position Statement on the Use of Anti-Obesity Drugs
Hermann Toplak et al.
OBESITY FACTS (2015)
European Guidelines for Obesity Management in Adults
Volkan Yumuk et al.
OBESITY FACTS (2015)
GUIDELINE OF ARGENTINA FEDERATION OF ENDOCRINOLOGY SOCIETIES ON DIAGNOSIS, PREVENTION AND TREATMENT OF VITAMIN D DEFICIENCY
Ariel Sanchez
ACTUALIZACIONES EN OSTEOLOGIA (2015)
Medical treatment of obesity: The past, the present and the future
George A. Bray
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2014)
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society
Michael D. Jensen et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Safety and Efficacy of Lorcaserin: A Combined Analysis of the BLOOM and BLOSSOM Trials
Louis Aronne et al.
POSTGRADUATE MEDICINE (2014)
EFFICACY OF PHENTERMINE MONOTHERAPY, TOPIRAMATE MONOTHERAPY, AND PHENTERMINE/TOPIRAMATE COMBINATION THERAPY ON WEIGHT LOSS: A NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIAL DATA
J. A. Thompson et al.
VALUE IN HEALTH (2014)
Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1
David G. Parkes et al.
EXPERT OPINION ON DRUG DISCOVERY (2013)
A Randomized, Phase 3 Trial of Naltrexone SR/Bupropion SR on Weight and Obesity-related Risk Factors (COR-II)
Caroline M. Apovian et al.
OBESITY (2013)
Obesity: The Gateway to Ill Health - an EASO Position Statement on a Rising Public Health, Clinical and Scientific Challenge in Europe
Gema Fruehbeck et al.
OBESITY FACTS (2013)
GRADE guidelines: 7. Rating the quality of evidence-inconsistency
Gordon H. Guyatt et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
GRADE guidelines: 8. Rating the quality of evidence-indirectness
Gordon H. Guyatt et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
GRADE guidelines: 5. Rating the quality of evidence-publication bias
Gordon H. Guyatt et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables
Gordon Guyatt et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias)
Gordon H. Guyatt et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
GRADE guidelines 6. Rating the quality of evidence-imprecision
Gordon H. Guyatt et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
Grading quality of evidence and strength of recommendations in clinical practice guidelines
J. L. Brozek et al.
ALLERGY (2009)
Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity
Raymond A. Plodkowski et al.
EXPERT OPINION ON PHARMACOTHERAPY (2009)
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
Arne Astrup et al.
LANCET (2009)
Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies
Gary Whitlock et al.
LANCET (2009)
Surgical treatment of obesity
Marielle J. F. Bult et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Developing clinical recommendations for breast, colorectal, and lung cancer adjuvant treatments using the GRADE system: A study from the programma Ricerca e Innovazione Emilia Romagna oncology research group
Rossana De Palma et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Lorcaserin, a novel selective human 5-Hydroxytryptamine2C agonist:: In vitro and in vivo pharmacological characterization
William J. Thomsen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
GRADE:: what is quality of evidence and why is it important to clinicians?
Gordon H. Guyatt et al.
BMJ-BRITISH MEDICAL JOURNAL (2008)
A case for clarity, consistency, and helpfulness: State-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system
Brian A. Swiglo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Orlistat: its current status as an anti-obesity drug
A Ballinger et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2002)
分享论文
